Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to... » read more

Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel

TOKYO, Jan 19, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe... » read more

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

TOKYO, Nov 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subsidiary of DKSH Holding... » read more

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

TOKYO, Oct 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan “EWAY Future & Beyond”, it has completed construction of the new injection/research building “Eisai Medicine Innovation Technology Solutions” (“EMITS”) at the Kawashima Industrial Park located in... » read more

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild... » read more

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

TOKYO, Apr 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party... » read more

Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments
Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments

CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered... » read more

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). The lecanemab... » read more

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

TOKYO, Jan 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant’s Development Code: RVT-2001) is... » read more

Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”
Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”

TOKYO, Nov 4, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it launches the “Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)”, a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for... » read more

Eisai to Join The Global Environmental Initiative “RE100”
Eisai to Join The Global Environmental Initiative “RE100”

TOKYO, Sep 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has joined “RE100”, the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity. RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy... » read more

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

TOKYO, Aug 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states:... » read more

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

Tokyo and New York, Jun 18, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines... » read more

Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

TOKYO, Jun 15, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. Zonegran is an antiepileptic drug (AED) originally created by Dainippon... » read more

Eisai’s Statement of Commitment for Carbon Neutrality by 2040
Eisai’s Statement of Commitment for Carbon Neutrality by 2040

TOKYO, May 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission which causes global warming, with an aim to achieve carbon neutral, and has set its new medium- to long-term target for achieving the goals. – Medium-term target: Achieving 100% renewable... » read more

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines,... » read more

Eisai Awarded The New Diversity Management Selection 100
Eisai Awarded The New Diversity Management Selection 100

TOKYO, Mar 22, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister’s Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was... » read more

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

TOKYO, Nov 18, 2020 – (JCN Newswire) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with... » read more